[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
July 2, 1982

Designing Appropriate Therapy in the Treatment of Gram-Negative Bacillary Meningitis

Author Affiliations

From the State University of New York Downstate Medical Center, Brooklyn (Drs Corrado and Gombert), and the Jewish Hospital and Medical Center of Brooklyn, Brooklyn, NY (Dr Cherubin).

JAMA. 1982;248(1):71-74. doi:10.1001/jama.1982.03330010045029

Gram-negative bacillary meningitis is being diagnosed more frequently, and the introduction of newer β-lactam antibiotics has contributed significantly to successful therapy. These new agents—because of their ease of administration and relative safety—also allow nonspecialists to treat the disease. There are, however, pitfalls in therapy of infections due to this heterogenous group of organisms. Extremely susceptible organisms, such as Escherichia coli and Klebsiella pneumoniae, most often respond to cephalosporin monotherapy, whereas relatively resistant organisms such as Acinetobacter and some Enterobacter may not. In these cases, combination therapy with an aminoglycoside is warranted. Testing the infecting organism for antibiotic susceptibility at the appropriate inoculum and pH may be useful in predicting therapeutic outcome.

(JAMA 1982;248:71-74)